Blog
Home / Blog

























Biosimilar competition has the potential to provide greater access to important treatments for America’s patients and cost savings for the… Read more »


















When it comes to ensuring medicines — including biosimilars — are safe and effective for patients, the FDA remains the… Read more »

Dr. Sameer Awsare, Internal Medicine Physician and Associate Executive Director at Kaiser Permanente Medical Group, sat down with the Biosimilars… Read more »



A recent series in Health Affairs questioned whether competition from biosimilar medicines is a viable path to providing relief from… Read more »

















The Naming of Biosimilar Medicines Worldwide Should Promote Patient Safety and Prescriber Confidence





Biosimilars hold great promise for patients seeking access to more affordable versions of critical medicines, but also for a health care system facing unsustainable, increasing costs. One of the most immediate challenges to biosimilars uptake in the United State sis the lack of […]

In the fast-paced world of health care, the role of the patient continues to evolve from passive to active. One of the most pressing issues patients face is the cost of their medications, which can serve as a significant barrier to access, especially for expensive brand-name biologic medicines[…]



On June 7th, The Atlantic presented “The Next Drugs: The Future for Biosimilars – An Atlantic Policy Update on Biosimilars” at the Newseum in Washington, D.C. The third in a series of Atlantic biosimilars briefings underwritten by The Biosimilars Council […]

Biosimilars not only have the unique ability to provide patients with much-needed access to lower-cost complex therapies, but also offer the potential for billions in patient, insurer and health system savings. But there are barriers […]

Working in coordination with The Atlantic, an award-winning publication that covers politics, business, and technology, The Biosimilars Council will continue its efforts to educate consumers about biosimilars by bringing together key stakeholders to debate the state and future of biosimilars […]

The country has undergone a great deal of change from December to today – but one thing that has not changed is that Americans want action to bring down the price of prescription drugs. A recent Kaiser Health Tracking Poll showed that over 60% of Americans believe lowering the cost of […]

On March 15th, The Atlantic presented “The Next Drugs: The Future for Biosimilars – An Atlantic Policy Briefing” at the Newseum in Washington, D.C. Underwritten by The Biosimilars Council, more than 100 influencers from across the […]